Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites


Creative Commons License

Gumusay O., Benekli M., EKİNCİ Ö. , Baykara M., ÖZET A. , Coskun U., ...More

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol.45, no.5, pp.416-421, 2015 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 45 Issue: 5
  • Publication Date: 2015
  • Doi Number: 10.1093/jjco/hyv020
  • Title of Journal : JAPANESE JOURNAL OF CLINICAL ONCOLOGY
  • Page Numbers: pp.416-421

Abstract

Objective: Determination of human epidermal growth factor receptor-2 status in advanced gastric cancer is important in clinical decision making. In the trastuzumab for GC trial, trastuzumab-based therapy demonstrated a significant overall survival benefit in patients with human epidermal growth factor receptor-2-positive advanced gastric cancer. Human epidermal growth factor receptor-2 discordance in gastric cancer primary and its metastases has been long debated. The aim of the study was to evaluate the rate of human epidermal growth factor receptor-2 discordance and its effect on treatment decisions in advanced gastric cancer.